Bioventix PLC (LON:BVXP - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 3,865.74 ($47.03) and traded as low as GBX 3,050 ($37.11). Bioventix shares last traded at GBX 3,250 ($39.54), with a volume of 4,369 shares traded.
Bioventix Stock Performance
The business's 50-day simple moving average is GBX 3,492.52 and its 200-day simple moving average is GBX 3,857.09. The company has a market capitalization of £164.68 million, a price-to-earnings ratio of 1,935.41 and a beta of 0.35.
Bioventix Increases Dividend
The firm also recently disclosed a dividend, which was paid on Thursday, November 21st. Shareholders of record on Thursday, November 7th were paid a GBX 87 ($1.06) dividend. The ex-dividend date of this dividend was Thursday, November 7th. This is a boost from Bioventix's previous dividend of $68.00. This represents a yield of 2.4%. Bioventix's dividend payout ratio (DPR) is presently 9,693.25%.
Insider Buying and Selling at Bioventix
In other news, insider Bruce Hiscock purchased 300 shares of the firm's stock in a transaction dated Wednesday, October 30th. The stock was bought at an average price of GBX 3,330 ($40.52) per share, with a total value of £9,990 ($12,154.76). In the last 90 days, insiders acquired 385 shares of company stock worth $1,107,381. Insiders own 8.02% of the company's stock.
About Bioventix
(
Get Free Report)
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.
Featured Articles
Before you consider Bioventix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventix wasn't on the list.
While Bioventix currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
